SCHEMBL4348140

SCHEMBL4348140

O=C1N=C(N2CCSCC2)SC1=Cc1ccc(C(=O)N2CCN(c3ncccc3Cl)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 3/20 0.46
DCTPP1 Q9H773 1/20 0.46
GRIN1 Q05586 3/20 0.44
GRIN2B Q13224 3/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.43
MAPT P10636 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
AMY1A P0DUB6 1/20 0.42
HDAC1 Q13547 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354746 1.00 ENPP2 (0.46) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4360746 0.91 ENPP2 (0.45) ENPP2DCTPP1ALDH1A1HTTMAPT
SCHEMBL4359199 0.91 ENPP2 (0.45) ENPP2DCTPP1ALDH1A1HTTMAPT
SCHEMBL4364677 0.82 ALDH1A1 (0.65) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4364671 0.82 ALDH1A1 (0.65) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4354018 0.81 ENPP2 (0.53) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4358777 0.81 MAPT (0.65) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4358781 0.81 MAPT (0.65) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4354015 0.81 ENPP2 (0.53) ENPP2DCTPP1GRIN1GRIN2BALDH1A1
SCHEMBL4356182 0.80 ENPP2 (0.43) ENPP2DCTPP1ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 ENPP2 1946/4885DCTPP1 167/4885GRIN1 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.